Yes. Multiple sclerosis frequently causes bladder and bowel incontinence, but not because the organs themselves are damaged. The disease disrupts the nerve signaling between the brain and spinal cord that coordinates storage and release. Bladder dysfunction affects an estimated 80 percent or more of people with MS at some point, and bowel symptoms affect roughly half to two-thirds. Both are treatable, and both are underreported because patients often assume nothing can be done.

The mechanism: a broken command chain

Bladder control depends on a three-part conversation. The detrusor muscle (the bladder wall) squeezes to empty. The internal and external sphincters hold urine in. A pontine switching center in the brainstem toggles the system between storage mode and voiding mode. In MS, demyelinating lesions can interrupt any link in that chain.

The most common pattern is detrusor overactivity. Lesions in the spinal cord or brainstem disrupt the inhibitory signals that normally keep the bladder quiet during filling. The result is a bladder that contracts involuntarily at low volumes. That produces urgency, frequency, and urge incontinence, meaning leakage happens before the person reaches a bathroom.

A second pattern is detrusor-sphincter dyssynergia. Here the bladder contracts while the sphincter fails to relax, because the coordinating signal between the two is lost. The bladder empties incompletely, and residual urine raises the risk of urinary tract infection and kidney strain. Some patients have a third pattern, an underactive bladder that cannot contract at all, which produces retention and overflow leakage.

Bowel control follows similar logic. The external anal sphincter and pelvic floor are voluntary muscles, but they depend on intact spinal pathways. Lesions that impair these pathways reduce the ability to defer a bowel movement when urgency strikes. Constipation is actually the more common bowel complaint in MS, and it matters because a loaded rectum provokes urgency and fecal incontinence. In plain terms: the plumbing works, but the wiring that says when to go has been scrambled.

How often, and who is affected

Prevalence estimates vary by setting and definition, but the pattern is consistent. Bladder dysfunction is reported in up to 80 percent of people with MS in clinical series, with a range of roughly 50 to 90 percent depending on disease duration and how symptoms are measured (National Multiple Sclerosis Society). Bowel dysfunction is reported in roughly 50 to 70 percent of patients. Both rise with disease duration and with spinal cord involvement.

Several clinical features predict higher risk. Lesions in the spinal cord rather than the brain are more strongly associated with bladder and bowel symptoms. Progressive forms of MS carry greater risk than relapsing forms. Longer time since diagnosis and higher disability scores raise the likelihood. Severity of symptoms does correlate roughly with lesion burden, but the correlation is not tight enough to predict any individual's course.

Pattern What goes wrong Typical symptoms Clinical concern
Detrusor overactivity Bladder contracts during filling Urgency, frequency, urge leakage Most common pattern in MS
Detrusor-sphincter dyssynergia Bladder and sphincter mismatch Incomplete emptying, hesitancy, dribbling High residual volumes, infection risk
Underactive detrusor Bladder cannot contract Retention, overflow leakage Silent unless residual checked
Constipation-predominant bowel Slow transit, pelvic floor dysfunction Straining, infrequency, bloating Can provoke fecal urgency
Fecal urgency and incontinence Impaired deferral of stool Sudden need to defecate, leakage Often tied to constipation and urgency

The counterintuitive part: leakage can mean retention

A professional caveat that changes management: leaking urine does not automatically mean an overactive bladder. In detrusor-sphincter dyssynergia, the bladder never empties properly, and the leakage is overflow. Treating that patient with anticholinergic bladder-relaxing drugs can worsen retention and, in rare cases, lead to kidney damage. This is why urodynamic testing or at minimum a post-void residual measurement matters before treatment. An estimated 10 to 20 percent of MS patients with bladder symptoms have significant incomplete emptying, and that subset needs a completely different plan.

Another counterintuitive detail concerns constipation. Many patients think of constipation and incontinence as opposites. In MS they are partners. A rectum loaded with hard stool triggers reflex urgency and can cause leakage of softer stool around the blockage, a pattern sometimes called overflow incontinence.

Red flags that need prompt evaluation

Fever with cloudy urine, flank pain, or new confusion, which may signal a urinary tract infection or kidney involvement. Inability to urinate at all, with lower abdominal pain and distension. New numbness in the saddle area, sudden severe weakness, or loss of bowel and bladder control together, which may indicate a spinal cord attack. Visible blood in urine. Rapidly worsening symptoms over days rather than months.

These warrant contact with a neurologist or urologist rather than watchful waiting. Some reflect infection, some reflect an acute MS relapse, and some reflect a structural problem unrelated to MS.

What actually helps: practical actions

Start with a bladder diary kept over three days, recording fluid intake, voiding times, volumes if measurable, and leakage episodes. Bring it to a clinician. It converts vague complaints into a pattern that guides testing.

Ask for a post-void residual measurement, ideally by bladder scan, before starting any bladder medication. A residual above roughly 100 to 150 milliliters suggests incomplete emptying and changes the treatment path. Pelvic floor physical therapy has good evidence for both bladder and bowel symptoms and is often underused.

Timed voiding, scheduled every two to three hours regardless of urge, reduces leakage episodes for many patients. Fluid management helps too: adequate but not excessive intake, and limiting caffeine and alcohol, which irritate the bladder. For bowel symptoms, a consistent toilet routine after breakfast, adequate fiber, and sufficient fluids are first-line measures.

Medication options exist for overactive bladder, including antimuscarinics and beta-3 agonists, but they require a clinician's assessment of emptying function. Constipation treatments range from dietary measures to osmotic laxatives to pelvic floor retraining. Neuromodulation and botulinum toxin injections into the bladder wall are options for refractory cases under specialist care. This article does not provide dosing or prescribing guidance; those decisions belong with a treating clinician.

Time course after an MS relapse What to expect Action
Days 1 to 7 New or worsening bladder or bowel symptoms appear Note symptoms, check for infection
Weeks 1 to 6 Symptoms may improve as inflammation settles Continue monitoring, avoid new bladder drugs without review
Weeks 6 to 12 Plateau identifies residual deficit Formal urology or continence assessment
Months 3 and beyond Persistent symptoms need a management plan Bladder diary, residual check, therapy referral
With progressive MS Gradual worsening without discrete relapses Reassess function annually

What the evidence cannot yet tell you

The evidence base has real limits. Most prevalence figures come from clinic populations, which overestimate symptom burden compared with community samples. Studies use inconsistent definitions of incontinence, so numbers are not directly comparable across papers. Urodynamic testing is not universally available, and many patients are treated empirically without it. There is no reliable way to predict from MRI findings alone which patient will develop which bladder pattern.

The reassuring core is stable and well established. MS causes incontinence through disrupted neural control, not organ failure. Most symptoms respond to structured assessment and treatment. The main failure is silence: patients who never mention the problem and clinicians who never ask. Raising the topic is the intervention with the best evidence behind it.

For authoritative guidance, the National Multiple Sclerosis Society and the International Continence Society publish patient and clinician resources on managing neurogenic bladder and bowel symptoms in MS.